Datavault AI Inc. (NASDAQ: DVLT) will report financial results for its second quarter of 2026 prior to market open on Wednesday, August 19, 2026. The Philadelphia-based provider of data monetization and real-world asset tokenization technologies aims to update investors on its operational progress and strategic initiatives in the Web 3.0 environment.

Following the release of the earnings data, Datavault AI will host a conference call and live webcast on the same day at 8:30 a.m. ET. CEO Nathaniel Bradley and CFO Brett Moyer are scheduled to present the company’s performance metrics and address questions from analysts and investors.

Conference Call Details

Investors can access the proceedings through the following channels:

A replay of the webcast will be available later in the day in the Investors/Presentations section of the Datavault AI website.

Business Overview

Datavault AI specializes in AI-driven data experiences, valuation, and monetization. Its cloud-based platform operates through two primary divisions:

• Acoustic Science Division: Includes WiSA, ADIO, and Sumerian patented technologies for spatial and multichannel wireless HD sound.
• Data Science Division: Harnesses Web 3.0 and high-performance computing for experiential data perception and secure monetization across sectors such as sports, biotech, fintech, and healthcare.

The company’s Information Data Exchange (IDE) enables Digital Twins and secure NIL licensing, fostering responsible AI with integrity. Its technology suite offers AI/ML automation, third-party integration, analytics, marketing automation, and advertising monitoring.

Forward-Looking Statements

The press release contains forward-looking statements regarding Datavault AI’s future events, including its full-year 2026 revenue target and expected operational outcomes. These statements involve risks and uncertainties, including potential failures to achieve revenue targets, deploy technologies successfully, or anticipate market trends correctly. Regulatory changes concerning digital assets may also impact operations. Investors are cautioned not to place undue reliance on these statements, as actual results may differ materially due to factors described in the company’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025.

Datavault AI Inc. (NASDAQ: DVLT) has expanded its technology licensing partnership with DataMeds AI, Inc. (NASDAQ: MEDS) to encompass the entire spectrum of commercial healthcare, healthspan, and wellness applications, moving beyond its initial focus on pharmaceutical distribution. This strategic amendment positions Datavault AI’s data monetization and real-world asset (RWA) tokenization technologies as a foundational layer for patient-controlled data transactions within the global health sector, which accounts for approximately 30% of worldwide data volume and is growing at an estimated 36% annually.

The amended definitive agreement alters the compensation structure for Datavault AI. The company will now receive common shares representing approximately 19.9% of DataMeds’ common stock upon the closing of related transactions, rather than the previously agreed-upon preferred shares. Management stated this adjustment was implemented to optimize the transaction for tax purposes. The value of these shares is expected to be categorized as revenue for Datavault AI once issued.

Transaction Structure and Closing Conditions

The share issuance to Datavault AI is contingent upon the satisfaction of specific closing conditions tied to concurrent transactions involving DataMeds. These conditions include:

• The acquisition of two QOLPOM intellectual property portfolios from EOS Technology Holdings, Inc.
• The acquisition of a controlling interest in Tollo Health LLC from HighBridge Advisors (referred to as HealthBridge Advisors in the agreement context).

DataMeds is executing these acquisitions in parallel with other entities, including Scilex Holding Company. The expansion of the licensing scope allows Datavault AI’s technology to integrate into DataMeds’ EinsteinRX Platform and PharmacyChain blockchain infrastructure, supporting data valuation and monetization across pharmacy, medical, laboratory, and wearable device settings.

Strategic Rationale and Market Context

Gerald Commissiong, Interim Co-CEO of DataMeds, emphasized that the partnership enables the transformation of data into a strategic asset for customer acquisition and commercial opportunities. "Our business model depends on extracting greater value from the information we generate every day," Commissiong said. "Datavault AI’s platform gives us confidence that we can transform data into a strategic asset... not just for operational insights, but as a foundation for future commercial opportunities."

Nathaniel T. Bradley, CEO of Datavault AI, noted that extending their platform into commercial healthcare is a natural progression for patient-controlled data. "DataMEDS gives us a focused path to put that technology to work so individuals have a say over how their own medical information is transacted," Bradley stated.

What the Numbers Show

The deal targets a significant segment of the global wellness economy, which the Global Wellness Institute valued at $6.8 trillion in 2024 and projects to reach $7.4 trillion in 2025. By integrating with DataMeds, Datavault AI aims to capture value from the rapid expansion of healthcare data, which L.E.K. Consulting estimates grows at a compound annual rate of 36%. The shift from preferred to common equity suggests a focus on long-term alignment and tax efficiency, though it exposes Datavault AI to the same market volatility as public shareholders of DataMeds.

Additional Corporate Developments

DataMeds, formerly known as Wellgistics Health, Inc., completed its corporate name change on July 21, 2026, with trading under the symbol ‘MEDS’ commencing on July 22, 2026. In a separate shareholder initiative, DataMeds announced a dividend of 50 Dream Bowl Meme Coin tokens for each share of common stock held as of the August 7, 2026 record date. This distribution is subject to change at DataMeds’ sole discretion.